Cited by

• Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.

  Kay J, Bock AE, Rehman M, Zhang W, Zhang M, Iikuni N, Alvarez DF. Kay J, et al. RMD Open. 2022 Sep;8(2):e002423. doi: 10.1136/rmdopen-2022-002423. RMD Open. 2022. PMID: 36180101 Free PMC article.
• [Revised version of the statement by the DGRh on biosimilars-update 2017].

  Braun J, Lorenz HM, Müller-Ladner U, Schneider M, Schulze-Koops H, Specker C, Strangfeld A, Wagner U, Dörner T. Braun J, et al. Z Rheumatol. 2018 Feb;77(1):81-90. doi: 10.1007/s00393-017-0407-0. Z Rheumatol. 2018. PMID: 29383440 German.
• Differentiating biosimilarity and comparability in biotherapeutics.

  Azevedo V, Hassett B, Fonseca JE, Atsumi T, Coindreau J, Jacobs I, Mahgoub E, O'Brien J, Singh E, Vicik S, Fitzpatrick B. Azevedo V, et al. Clin Rheumatol. 2016 Dec;35(12):2877-2886. doi: 10.1007/s10067-016-3427-2. Epub 2016 Oct 12. Clin Rheumatol. 2016. PMID: 27734233 Review.
• Degree of prescriber's knowledge about variability in biological drugs "innovators" in manufacturing process.

  Jiménez-Pichardo L, Gázquez-Pérez R, Sierra-Sánchez JF. Jiménez-Pichardo L, et al. Eur J Clin Pharmacol. 2018 Apr;74(4):505-511. doi: 10.1007/s00228-017-2397-x. Epub 2017 Dec 15. Eur J Clin Pharmacol. 2018. PMID: 29247389
• A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

  Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Choi J, Rho YH, Smolen JS. Choe JY, et al. Ann Rheum Dis. 2017 Jan;76(1):58-64. doi: 10.1136/annrheumdis-2015-207764. Epub 2015 Aug 28. Ann Rheum Dis. 2017. PMID: 26318384 Free PMC article. Clinical Trial.